程序性死亡配體1(PD-L1)又稱CD274或B7同源物1(B7-H1)，是一種跨膜蛋白，通過與程序性死亡-1(PD-1)受體的結合，抑制免疫系統，使腫瘤細胞抵抗CD8+T細胞介導的殺傷。PD-L1的過度表達可能使癌細胞逃避宿主免疫系統的作用。在腎細胞癌中，PD-L1的表達上調與腫瘤侵襲性和死亡風險增加有關，而在卵巢癌中，PD-L1的高表達會導致明顯的不良預后。PD-L1還與系統性紅斑狼瘡和皮膚黑色素瘤有關。當與CD8+腫瘤浸潤淋巴細胞密度聯合考慮時，PD-L1的表達水平可能是預測多種癌癥類型的有用指標，包括III期非小細胞肺癌、激素受體陰性乳腺癌和前哨淋巴結黑色素瘤。

Programmed Death-Ligand 1 (PD-L1), also known as CD274 or B7 Homolog 1 (B7-H1), is a transmembrane protein involved in suppressing the immune system and rendering tumor cells resistant to CD8+ T cell-mediated lysis through binding of the Programmed Death-1 (PD-1) receptor. Overexpression of PD-L1 may allow cancer cells to evade the actions of the host immune system. In renal cell carcinoma, upregulation of PD-L1 has been linked to increased tumor aggressiveness and risk of death, and, in ovarian cancer, higher expression of this protein has lead to significantly poorer prognosis. PD-L1 has also been linked to systemic lupus erythematosus and cutaneous melanoma. When considered in adjunct with CD8+ tumor-infiltrating lymphocyte density, expression levels of PD-L1 may be a useful predictor of multiple cancer types, including stage III non-small cell lung cancer, hormone receptor negative breast cancer, and sentinel lymph node melanoma.

 

Clone IHC411

Source Rabbit Monoclonal

Positive Control Tonsil, Lung Adenocarcinoma

Dilution Range 1:50-1:200

 

Ostrand-Rosenberg S, et al. J Immunol. 2014; 193:3835-41.

Tokito T, et al. Eur J Cancer. 2016; 55:7-14.

Park IH, et al. Clin Breast Cancer. 2016; 16:51-8.

Kakavand H, et al. Mod Pathol. 2015; 28: 1535-44.

Xia B, et al. Immunotherapy. 2016; 8:279-98.

Patel SP, et al. Mol Cancer Ther. 2015; 14:847-56.

Singh BP, et al. Cancers (Basel). 2016; 8.

Chemnitz JM, et al. J Immunol. 2004; 173:945–54.

Thompson RH, et al. Proc Natl Acad Sci USA. 2004; 101:17174–9.

Hamanishi J, et al. Proc Natl Acad Sci USA. 2007; 104:3360–5.

Mozaffarian N, et al. Rheumatology, 2008; 47:1335–41.